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Abstract
Between 2000–2012, the national estimated incidence rate of pediatric mastoiditis, a rare but 
serious complication of acute otitis media (AOM), was highest in 2006 (2.7 per 100,000 
population) and lowest in 2012 (1.8 per 100,000 population). This measure provides a baseline for 
public health surveillance in the pneumococcal conjugate vaccine era as stewardship efforts target 
antibiotic use in AOM.
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Introduction
Mastoiditis is a rare but serious complication of acute otitis media (AOM). AOM accounts 
for almost one-quarter of antibiotic prescriptions for children in ambulatory settings1, 2 and 
therefore is an important antibiotic stewardship target. Visits with AOM diagnoses decreased 
in recent years, coinciding with declines in antibiotic prescriptions for AOM.3, 4 The 
American Academy of Pediatrics recommends watchful waiting in selected cases of AOM 
but cautions that withholding antibiotics in all cases could lead to increases in suppurative 
complications, such as mastoiditis.5
Mastoiditis surveillance can be used as a public health metric to identify if increases in this 
rare complication coincide with decreases in rates of diagnosis and associated antibiotic 
treatment for AOM. This approach has been used in other countries, such as Sweden6 and 
the United Kingdom.7 The introduction of pneunomococcal conjugate vaccines (PCV; PCV7 
in 2000 and PCV13 in 2010) has been associated with reductions in and changing of the 
epidemiology of AOM.8, 9 The objective of this study is to establish regional and temporal 
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trends in the incidence of pediatric mastoiditis in the United States in the PCV-era (2000–
2012) as a baseline for public health surveillance of unintended consequences of reducing 
antibiotic use for AOM.
Materials and Methods
Data sources and study population
We identified incident mastoiditis discharges among children (<18 years) in the Kid’s 
Inpatient Database (KID), part of the Healthcare Cost and Utilization Project. We defined a 
mastoiditis case as a hospital discharge with acute or unspecified mastoiditis using the 
following primary International Classification of Diseases, Ninth Revision, Clinical 
Modification (ICD-9) codes: acute mastoiditis with no complications (383.00), subperiosteal 
abscess of mastoid (383.01), acute mastoiditis with complications (383.02), and unspecified 
mastoiditis (383.9). We excluded discharges with an additional ICD-9 code for chronic 
mastoiditis (383.1). One year of data from KID is released every three years; we used all 
available years since 2000. HCUP databases are considered limited datasets and non-human 
subjects, as determined by the National Center for Emerging and Zoonotic Infectious 
Diseases human subjects advisor.
We derived population size from the U.S. Census Bureau Vintage 2015 Bridged-Race 
Postcensal Population Estimates for each year, region, age, and sex group. Although race is 
available in both KID and census estimates, it was excluded from this analysis as 
categorizations differed between the two sources.
Statistical Analysis
We estimated national incidence and 95% confidence intervals (CI) using methods for 
complex samples. We estimated annual incidence rates nationally, by age group (<2 and 2–
17 years), sex, and region (Northeast, Midwest, South and West) by dividing the estimated 
number of incident cases by census estimates for each group. Age was dichotomized based 
upon different guideline-recommended AOM management strategies for children aged <2 
and 2–17 years old.5 Estimates from KID have variance due to sampling variability while 
census estimates do not. To account for this difference, 95% confidence intervals (CIs) for 
incidence rates were calculated using the corresponding upper and lower limit estimates of 
mastoiditis incidence from KID divided by census estimates. We estimated rate ratios using 
a no-interaction negative binomial model adjusting for age, sex, and region with the year 
2000 as the referent. As there was significant interaction between region and year, we 
estimated region-level trends using a model accounting for this interaction and adjusting for 
age and sex. Statistical tests were conducted at the α = 0.05 level. All analyses were 
conducted using SAS 9.4 (Cary, NC).
We also performed sensitivity analyses using (1) acute diagnosis codes in the primary 
diagnosis position, and (2) acute and unspecified codes in any of the first 15 discharge 
codes, the maximum number of diagnostic codes in all years of data.
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Results
During the study period, the estimated annual number of discharges with a primary 
diagnosis of mastoiditis ranged from 1,326 (95% CI 1,180–1,471) to 1,969 (95% CI 1,776–
2,163) (see Supplemental Digital Content 1). The per population estimated mastoiditis 
incidence rates increased from 2.3 (95% CI 2.1–2.6) per 100,000 population in 2000 to 2.7 
(95% CI 2.4–2.9) per 100,000 in 2006, then decreased to 1.8 (95% CI 1.6–2.0) per 100,000 
in 2012 (Table 1). The incidence rate was over 20% lower in 2012 than in 2000 (adjusted 
Rate Ratio [aRR] 0.8, 95% CI 0.6–0.9); this was the only year with significantly lower 
incidence rates than 2000. Rates were higher among those younger than 2 years and among 
males (Table 1).
Temporal trends varied by region with no single region consistently having the highest or 
lowest rates (Table 1). Incidence rates decreased from 2000 to 2012 in all regions except the 
Midwest. These decreases were only significant in the West and the South (West: aRR 0.6, 
95% CI 0.5–0.8; South: aRR 0.6, 95% CI 0.5–0.8). The South had the highest rates of 
mastoiditis in 2000–2006 and the Northeast had the highest rates in 2009–2012.
Sensitivity analyses demonstrated that estimates using the broadest case definition (acute 
and unspecified diagnosis codes in any position) were 2–3 times higher than estimates using 
the narrowest definition (acute diagnosis codes in the primary position; see Supplemental 
Digital Content 2). Overall trends by year, geographic area, age group, and sex were similar 
across case definitions.
Discussion
Mastoiditis incidence rates in the United States increased from 2000 to 2006 and then 
decreased from 2006 to 2012. Compared with 2000, incidence rates were only significantly 
lower in 2012. No one region consistently had the highest or lowest rates in every year of the 
study period. The declining mastoiditis incidence rates in the latter half of the study period 
(2006 to 2012) coincided with decreasing visits with a diagnosis of AOM and subsequent 
antibiotic prescriptions for AOM observed in other published studies during the same period.
3, 8, 9
Although the total number of antibiotic prescriptions for AOM declined, this trend was 
driven by decreasing visits with an AOM diagnosis; the proportion of AOM diagnoses 
treated with antibiotics decreased only slightly.3 Observed decreases in AOM diagnoses are 
likely multifactorial and related to vaccine uptake, including PCV introduction and the 
universal annual influenza vaccination recommendation, application of stricter diagnostic 
criteria, and perhaps changes in care-seeking behaviors.3, 5, 8, 9 Despite 2004 and 2013 
guidelines from the American Academy of Pediatrics recommending watchful waiting, 
concern over complications, including mastoiditis, may have discouraged physicians from 
adopting watchful waiting in AOM management.10 Antibiotic treatment decreases the 
relative risk of mastoiditis by half.7 However, because mastoiditis is very rare, the absolute 
increase that would be expected without antibiotic treatment would be two additional 
mastoiditis cases per 10,000 cases of AOM.7 The American Academy of Pediatrics 
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guidelines recommend antibiotics in many cases of AOM, in part, to prevent increases in the 
incidence of suppurative complications, including mastoiditis.5 In the context of declining 
rates of AOM diagnosis and associated treatment, it is reassuring that our study 
demonstrates that mastoiditis incidence has not increased in recent years.
Annual mastoiditis incidence rates were lowest in the West or Midwest, regions with lower 
rates of AOM diagnoses and associated antibiotic use.2 This pattern argues against 
underdiagnosis and undertreatment of AOM in those regions. Reasons for regional 
differences are unknown, but possibilities include differences in underlying risk factors, 
higher rates of AOM, and coding differences.
Sensitivity analyses show variation in incidence rate estimates by case definition, 
highlighting the role of both true incidence and coding practices in mastoiditis incidence 
estimation using discharge codes. Temporal and regional trends are consistent across 
definitions, suggesting true incidence changes rather than measurement differences. 
Additional conditions, such as bacterial meningitis, sigmoid sinus thrombosis, and 
intracranial abscesses could potentially add to our understanding of the safety of reducing 
antibiotic use for AOM. However, mastoiditis, as the most common severe complication of 
AOM, may provide a more easily observable metric.
Our study has several limitations. The first limitation is that we could not account for many 
factors that may contribute to acute mastoiditis, such as antecedent OM, antibiotic use, 
vaccination status, and underlying health. Although we can contextualize our findings with 
published data on these factors, we cannot directly correlate incidence with these factors in 
our study population. Another limitation is that estimates are only available every three years 
from KID (next release 2016 data in mid-2018). This may impede our ability to see year-
over-year shifts, which is potentially important in identifying trends. A third limitation is 
that KID aggregates state-level data with variability in the number of states submitting data 
and in the data fields submitted over time. A strength of our study is the ability to estimate 
national incidence of this rare disease. The inclusion of a sensitivity analysis is also a 
strength as it allows us to account for both changes in true incidence and coding practices.
This study of mastoiditis among U.S. children from 2000 to 2012 estimated incidence rates 
over time and across regions, sexes, and age groups in the PCV era. These estimates may 
serve as a baseline for public health surveillance of this rare complication and could be used 
to monitor for uninteded consequences of reducing antibiotic use for AOM, potentially 
informing antibiotic stewardship efforts.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Table 1.
National estimated incidence rate of mastoiditisa per 100,000 population, Kid’s Inpatient Database (KID), 
2000–2012
Estimated mastoiditisa incidence rate per 100,000 population (95% CI)b
2000 2003 2006 2009 2012
Total 2.3 (2.1, 2.6) 2.5 (2.3, 2.8) 2.7 (2.4, 2.9) 2.3 (2.1, 2.6) 1.8 (1.6, 2.0)
Sex
Female 2.0 (1.7, 2.3) 2.1 (1.9, 2.4) 2.3 (2.0, 2.6) 2.0 (1.7, 2.3) 1.6 (1.4, 1.8)
Male 2.6 (2.3, 3.0) 2.8 (2.5, 3.1) 2.9 (2.6, 3.3) 2.6 (2.3, 2.9) 2.0 (1.8, 2.3)
Age, in years
<2 6.2 (5.2, 7.2) 5.3 (4.5, 6.0) 7.1 (6.2, 8.0) 7.0 (6.0, 8.1) 3.5 (2.9, 4.0)
2–17 1.9 (1.6, 2.1) 2.2 (1.9, 2.4) 2.1 (1.9, 2.3) 1.7 (1.5, 1.9) 1.6 (1.4, 1.8)
Region
Northeast 2.1 (1.6, 2.5) 2.5 (1.9, 3.1) 2.5 (1.9, 3.1) 2.6 (1.9, 3.3) 2.0 (1.5, 2.6)
Midwest 1.7 (1.0, 2.4) 2.5 (1.9, 3.1) 2.4 (1.8, 3.0) 2.2 (1.5, 2.9) 1.8 (1.3, 2.2)
South 2.9 (2.3, 3.4) 2.7 (2.2, 3.2) 2.9 (2.3, 3.6) 2.5 (2.0, 3.0) 1.9 (1.5, 2.2)
West 2.4 (1.9, 2.9) 2.3 (1.8, 2.9) 2.6 (2.0, 3.2) 2.0 (1.6, 2.5) 1.6 (1.2, 2.0)
Adjusted Rate Ratioc (95% CI) Referent 1.0 (0.9, 1.2) 1.1 (1.0, 1.3) 1.0 (0.9, 1.2) 0.8 (0.6, 0.9)
a
Defined as a discharge with ICD-9 codes 383.00, 383.01, 383.02, 383.9 in the primary position.
bUpper and lower 95% CIs of incidence rates were calculated using the corresponding limits from estimates of incident mastoiditis cases derived 
from the KID divided by the census estimate.
c
Estimated using a no-interaction negative binomial model adjusted for age, sex, and region. Ratio and confidence intervals calculated using 
incidence point estimate.
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